RareiTi, Inc.

Managed Access | Better Outcomes
RareiTi offers a new system of managed access for people and communities across the globe in the rare disease space.

[RareiTi, Inc. @RareiTi]

We are delighted to announce our Advisory Board: @JaneGriffiths_1, Martin Andrews, @cadelarge , John Doux, & @Joff_Masukawa. So excited to welcome these accomplished execs & industry leaders.
#leadership #pressrelease #advisoryboard #rarediseases

https://t.co/vQFckXeEnP

[RareiTi, Inc. @RareiTi]

New RareiTiVIEW from CEO Alex Evans: Patient Experience Data takes the daily experience of patients and translates it into essential insights. #PatientExperience #patientengagement #patientdata
https://t.co/3jB5f2Pw0g

[RareiTi, Inc. @RareiTi]

Taking the extra step to make sure your patient engagement and insights are meaningful isn't just the right thing to do - it is the smartest business decision you can make.

https://t.co/neKK2ceGsB

[RareiTi, Inc. @RareiTi]

From @Forbes: A great example of how taking advantage of mobile technology can reduce stress on clinicians and provide better engagement and outcomes for the patient.
https://t.co/RmAOOYR8bt

[RareiTi, Inc. @RareiTi]

Key quote: "Patient groups are trusted sources that pharma could work through to share what they're doing and make drugs more accessible."

Trust is built with consistent and direct communication with patient communities.
https://t.co/0UCIUDEcXC

[RareiTi, Inc. @RareiTi]

From RareiTi CEO Alex Evans: Telemedicine offers better ways for everyone, especially the vulnerable, to access healthcare. We must continue to embrace these digital innovations even after the pandemic subsides.

https://t.co/XtN7hXB8MI

[RareiTi, Inc. @RareiTi]

If your company is interested in our industry-leading expertise or technical demos, contact RareiTi at https://t.co/V5ohKP6cvS

[RareiTi, Inc. @RareiTi]

From the RareiTi Blog:

We are living in a pivotal moment for the biopharma industry. Those that seize the moment and take advantage of the innovations of the past year will be the ones to find success.

https://t.co/j1OGTOVdMv

[RareiTi, Inc. @RareiTi]

The new norm from the pandemic presents an opportunity to rethink how we approach data. Moving forward, large-scale MAPs will be the expectation, not the exception.

https://t.co/r8KRTMGBQA

[RareiTi, Inc. @RareiTi]

Rare disease care and treatment are emotionally challenging. Is it any wonder that such difficult conversations spill into the public consciousness?

Read some thoughts from RareiTi Co-Founder Natalie Douglas on the recent public debate: https://t.co/QMUxIKW9BS

[RareiTi, Inc. @RareiTi]

In Rare Disease, collaboration matters. That's why organizations like ICORD, which bring together leaders like Co-Founder Wendy White from across the globe, are vital to creating better outcomes for all rare disease stakeholders. #RareDisease

https://t.co/cFzeWLWNRi

[RareiTi, Inc. @RareiTi]

If you would like to discuss or have questions about how working across silos for a coordinated and strategic approach can actualize your rare disease promise, contact RareiTi.

[RareiTi, Inc. @RareiTi]

Writing a check for a patient advocacy group is not enough. There are no shortcuts when it comes to true patient centricity. It means being there for their entire physical and emotional journey.

[RareiTi, Inc. @RareiTi]

RareiTi Co-Founder Wendy White named to the board of ICORD, the International Collaboration on Rare Diseases and Orphan Drugs #RareDiseases #healthcare

https://t.co/cFzeWLWNRi

[RareiTi, Inc. @RareiTi]

Like Oncology trials, RareiTi believes that multi-phase selective placebo-controlled trials are not the only option that should be considered. In rare disease, patients can’t afford to be patient. (2/2)
#raredisease #earlyaccess #healthcare

[RareiTi, Inc. @RareiTi]

In response to demand from the ALS community and the public, on April 27, Biogen made the decision to prioritize early access to tofersen to treat patients with the most dire form of SOD1-mutant ALS. (1/2)

[Lisa's Legacy for ALS @LisaLegacy4ALS]

Please read Lisa's statement re: @Biogen's decision to deny her access (for 5th time) to #tofersen. #drugsinbodes #dyingwaiting #ItsTime

[RareiTi, Inc. @RareiTi]

What is RareiTi Mind? We help achieve your business objectives with our deep knowledge of the complex rare disease environment, global regulatory requirements, patient advocacy connections and managed access ecosystem experience.

https://t.co/u4VF5ON43u

[RareiTi, Inc. @RareiTi]

Last week our Co-founder Alex Evans on being named a director of the Rare Disease Nurse Network. (RDNN) Congratulations! #healthcare #raredisease #publichealth #digitalhealth #nurse #innovation

https://t.co/B0pkNOc86b

[RareiTi, Inc. @RareiTi]

RareiTi CEO Alex Evans, RN, has become a director of the Rare Disease Nurse Network (RDNN), an organization of nurses, industry leaders, and others committed to providing specialist nurse support for every person with a rare disease.

https://t.co/0K1MfWF9NI

[RareiTi, Inc. @RareiTi]

"Our goal remains focused around access to therapies, but the pandemic is a reminder.. that country-specific outreach to patients and providers is crucial to getting emerging therapies in the hands of those who need them most." #pandemic #raredisease

https://t.co/u5gmpC6FDH